Targeting of PI3K/AKT signaling and DNA damage response in acute myeloid leukemia: a novel therapeutic strategy to boost chemotherapy response and overcome resistance
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Targeting of PI3K/AKT signaling and DNA damage response in acute myeloid leukemia : a novel therapeutic strategy to boost chemotherapy response and overcome resistance. / Estruch, Montserrat; Vittori, Camilla; Montesinos, Teresa Muñoz; Reckzeh, Kristian; Theilgaard-Mönch, Kim.
I: Cancer Drug Resistance, Bind 4, 2021, s. 984-995.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Targeting of PI3K/AKT signaling and DNA damage response in acute myeloid leukemia
T2 - a novel therapeutic strategy to boost chemotherapy response and overcome resistance
AU - Estruch, Montserrat
AU - Vittori, Camilla
AU - Montesinos, Teresa Muñoz
AU - Reckzeh, Kristian
AU - Theilgaard-Mönch, Kim
PY - 2021
Y1 - 2021
N2 - Resistance of cancer patients to DNA damaging radiation therapy and chemotherapy remains a major problem in the clinic. The current review discusses the molecular mechanisms of therapy resistance in acute myeloid leukemia (AML) conferred by cooperative chemotherapy-induced DNA damage response (DDR) and mutational activation of PI3K/AKT signaling. In addition, strategies to overcome resistance are discussed, with particular focus on studies underpinning the vast potential of therapies combining standard chemotherapy AML regimens with small molecule inhibitors targeting key regulatory hubs at the interface of DDR and oncogenic signaling pathways.
AB - Resistance of cancer patients to DNA damaging radiation therapy and chemotherapy remains a major problem in the clinic. The current review discusses the molecular mechanisms of therapy resistance in acute myeloid leukemia (AML) conferred by cooperative chemotherapy-induced DNA damage response (DDR) and mutational activation of PI3K/AKT signaling. In addition, strategies to overcome resistance are discussed, with particular focus on studies underpinning the vast potential of therapies combining standard chemotherapy AML regimens with small molecule inhibitors targeting key regulatory hubs at the interface of DDR and oncogenic signaling pathways.
U2 - 10.20517/cdr.2021.76
DO - 10.20517/cdr.2021.76
M3 - Journal article
C2 - 35582388
VL - 4
SP - 984
EP - 995
JO - Cancer Drug Resistance
JF - Cancer Drug Resistance
SN - 2578-532X
ER -
ID: 290252268